Abstract: The subject invention is directed to a pharmaceutical composition comprising an open matrix network carrying a pharmaceutically active ingredient, wherein the open matrix network comprises inulin.

Abstract: In general, the present invention is related to biopolymer and biocomposite materials and structures, and methods of making and using the same. In some embodiments, the present invention is directed to oriented collagen based biocomposite materials and structures, and methods of making.

Abstract: A topical therapeutic hydrophobic breakable composition includes a carrier comprising (a) about 60% to about 99% by weight of at least one hydrophobic oil; (b) at least one viscosity-modifying agents selected from the group consisting of a fatty alcohol, a fatty acid and a wax; and (c) a tetracycline antibiotic, characterized in that at least part of the tetracycline antibiotic is suspended in the composition; the viscosity of the composition is at least about 30% higher than the viscosity of the carrier without the tetracycline antibiotic; and is higher than the viscosity of the hydrophobic oil and the tetracycline antibiotic without the viscosity modifying agents; and the amount of viscosity modifying agents can optionally be reduced by at least an amount by weight that would have increased the viscosity of the carrier without the tetracycline antibiotic by at least 30%; wherein the tetracycline is chemically stable in the composition for at least six months; wherein more than about 90% of the tetracycline

Abstract: This disclosure relates to an improved process for the preparation of carbohydrate conjugates. The disclosure also relates to carbohydrate conjugated iRNA agents comprising these carbohydrate conjugates, which have improved purity and are advantageous for the in vivo delivery of the iRNA agents.

Abstract: The invention relates to a drug conjugate including a drug and a plant steroid. The drug conjugate may target the drug for intestinal cell delivery, and thus may be used to treat diseases, including intestinal diseases, or to affect intestinal metabolism. The invention therefore also relates to treating intestinal diseases and affecting intestinal metabolism with the drug conjugate.

Abstract: The present invention relates to polydixylitol polymer based gene transporter (PdXYP) and a preparation method thereof. Further, the present invention relates to a nucleic acid delivery complex where the nucleic acids for treatment are conjugated to the gene transporter and a pharmaceutical composition for gene therapy including the complex as an active ingredient. In addition, the present invention relates to the gene transporter, gene delivery complex, and gene therapy using the gene transporter and gene delivery complex. It was confirmed that the PdXYP of the present invention has a considerably higher nucleic acid delivery rate than existing gene transporters, has almost no cytotoxicity in the conjugate when conjugated with DNA, also has very high in vivo transfection efficiency, and above all, especially has considerably high transfection efficiency for brain tissues, which has involved difficulty in gene therapy due to the blood brain barrier for a while.

Abstract: The present disclosure provides POZ derivatives having a range of active functional groups allowing conjugation of POZ derivatives to a variety of target molecules under a wide range of reaction conditions to produce a hydrolytically stable target molecule-POZ conjugate. Furthermore, the present disclosure provides novel methods of synthesis for the disclosed POZ derivatives and hydrolytically stable target molecule-POZ conjugates created using the disclosed terminally activated monofunctional POZ derivatives. In one embodiment, the POZ derivative is a terminally activated monofunctional POZ derivative.

Abstract: Cytotoxic dimers comprising CBI-based and/or CPI-based sub-units, antibody drug conjugates comprising such dimers, and to methods for using the same to treat cancer and other conditions.

Abstract: In various embodiments a payload molecule or drug molecule delivery system is disclosed. The system comprises a plurality of functionalized discrete carbon nanotubes having specific properties. The composition can comprise a plurality of discrete carbon nanotubes that have at least a portion of the carbon nanotubes with a number average (ratio of number average contour length to end to end length) of greater than 1.1 and up to about 3. These discrete carbon nanotubes having the specified ratio of number average (tube contour length (TCL) to number average tube end-end length (TEE)) ratio are not only discrete (separated) from one another, but are also controlled in their alignment such that processability and mechanical strength properties are both enhanced. Utility of the molecular rebar composition includes, but is not limited to improved payload molecule delivery, such as drug delivery, into body of an animal, such as human.

Abstract: A particulate, modified release barrier coated drug-cation exchange resin complex comprising a core composed of a drug complexed with a pharmaceutically acceptable ion-exchange resin is provided. Methods of making and products containing this coated complex are described.

Abstract: The invention provides an expression system for producing Caveolin-1 in neuronal cells or neural stem cells comprising a neuron-specific regulatory element and a nucleic acid sequence encoding Caveolin-1.

Abstract: The present invention provides compositions, systems, kits, and methods for generating expression of one or more proteins and/or biologically active nucleic acid molecules in a subject (e.g., at therapeutic levels for extended periods required to produce therapeutic effects). In certain embodiments, systems and kits are provided that comprise a first composition comprising a first amount of polycationic structures, and a second composition comprising a therapeutically effective amount of expression vectors (e.g., non-viral expression vectors not associated with liposomes) that are CpG-free or CpG-reduced, where the expression vectors comprise a first nucleic acid sequence encoding: i) a first therapeutic protein or proteins, and/or ii) a first biologically active nucleic acid molecule or molecules.

Abstract: The present invention aims at providing a novel indocyanine compound solving problems of conventionally used indocyanine green, such as solubility in water or physiological saline, a synthesis method and a purification method thereof, and a diagnostic composition including the novel indocyanine compound. Further, provided are a method for evaluating biokinetics of the novel indocyanine compound and a device for measuring biokinetics, and a method and a device for visualizing circulation of fluid such as blood in a living body, which utilize the diagnostic composition. Also, found are a novel indocyanine compound in which a hydrophobic moiety in a near-infrared fluorescent indocyanine molecule is included in a cavity of a cyclic sugar chain cyclodextrin to cover the hydrophobic moiety in the indocyanine molecule with the glucose, and a synthesis method and a purification method thereof.

Abstract: The present disclosure relates to a novel type of recognitive biodegradable nanoparticles and their preparations. In particular, the present disclosure relates to combinations of MIPs and biodegradable nanoparticles.

Abstract: Systems, methods and related devices used to produce and collect polarized noble gas to inhibit, suppress, detect or filter alkali metal nanoclusters to preserve or increase a polarization level thereof. The systems can include a pre-sat chamber that has an Area Ratio between 20 and 500.

Abstract: Disclosed herein is a nanosensor of miRNA activity in a target cell, and methods of use, for detection and diagnostic applications. The nanosensor comprises a delivery particle comprising an iron oxide crystal coated with a polymer; and a sensor oligonucleotide covalently attached to the polymer. The sensor oligonucleotide comprises a seed region, comprising a nucleic acid sequence that is completely complementary to the target miRNA and comprises a cleavage site which can be engaged and cleaved by the target miRNA.

Abstract: A method of preparing a coated nanoparticle can include decomposing a compound to produce a nanoparticle, oxidizing the nanoparticle to produce an oxidized nanoparticle, and coating the oxidized nanoparticle with a zwitterionic ligand to produce the coated nanoparticle. The coated nanoparticle or the nanoparticle can be used in magnetic resonance imaging.

Abstract: A rod-shaped plant virus having an interior surface and an exterior surface, and at least one imaging agent that is linked to the interior and/or exterior surface is described. The rod-shaped viruses can be combined into larger spherical nanoparticles. A rod-shaped plant virus or spherical nanoparticles including an imaging agent can be used in a method of generating an image of a tissue region of a subject such as a tumor or atherosclerotic tissue by administering the virus particle to the subject and generating an image of the tissue region of the subject to which the virus particle has been distributed.

Abstract: Metal complexes including a radionuclide and a compound of Formula I and Formula II are potent inhibitors of PSMA.

Abstract: Provided is a decontamination apparatus including a base, and a source that emits UVC light at a suitable intensity to at least partially decontaminate a target object and render the target object pathogen reduced. An adjustable support is coupled to the base and includes an adjustment mechanism that can be manipulated to adjust a position of the source relative to the base. A controller is operatively connected to the source to control emission of the UVC light and establish at least one of a suitable duration of a decontamination process and a suitable intensity of UVC light to render the target object pathogen reduced.

Abstract: Generally discussed herein are systems, apparatuses, and methods for decontamination and/or sanitization. A system may include a water inlet to provide water to a first conduit, an outlet to provide a fluid to an end user, a catholyte tank to provide catholyte to a second conduit, an anolyte tank to provide anolyte to a third conduit, and an adapter coupled to the first, second, and third conduits, the adapter including one or more fluid paths therethrough to the outlet, the adapter to selectively provide one or more of the water, the catholyte, and the anolyte as the fluid.

Abstract: A sterilization system including an oxygen generator, an ozone generator, a mixer, a wash chamber, and a sterilization chamber is disclosed. The oxygen generator is configured to generate a flow of oxygen. The ozone generator is in fluid communication with the oxygen generator, and configured to generate a flow of ozone from the flow of oxygen. The mixer is in fluid communication with the ozone generator and configured to receive the flow of ozone and a flow of cleaning fluid, and mix the flow of ozone into the flow of cleaning fluid, resulting in a flow of ozonated cleaning fluid. The wash chamber is in fluid communication with the mixer and configured to receive the flow of ozonated cleaning fluid from the mixer. The sterilization chamber is in fluid communication with the ozone generator and is configure to receive the flow of ozone.

Abstract: A sterilization cabinet, comprising a top panel, at least two side panels, and a floor panel forming a part of a chamber of the sterilization cabinet; at least one door connected to at least one of the at least two side panels of the sterilization cabinet; a vent formed in at least one of the two side panels; at least one first filter covering the vent and a filter cover configured to hold the first filter against the vent; a drain positioned in the floor panel, wherein the floor panel has a slope configured to cause condensate within the chamber to flow into the drain and wherein the drain is the only outlet for the condensate along the floor panel; and a second filter covering the drain such that condensate flowing into the drain passes through the second filter.

Abstract: It is an object of the present invention to provide a deodorant or a deodorant composition which has excellent deodorizing performance with respect to sulfurous stench from methyl mercaptan and hydrogen sulfide and the like. It is another object of the present invention to provide a deodorant or a deodorant composition which maintains a deodorizing effect with respect to sulfurous stench and which makes it possible to suppress resin deterioration in the case of being kneaded into a resin, and a deodorizing product containing the same. A deodorant of the present invention contains amorphous copper silicate represented by the following formula [1]: xNa2O.yCuO.SiO2.zH2O??[1] wherein, in formula [1], x is a positive number from 0.002 to 0.040, y is a positive number from 0.07 to 0.48, and z is a positive number from 0.02 to 0.30.

Abstract: A wax warmer includes a body, a reservoir, and a plate. The reservoir is adapted to receive a wax melt. The plate is disposed adjacent to the body and the reservoir. A first surface of the plate is in thermal communication with the reservoir. A retention bracket is provided on a second surface of the plate. A threaded shaft extends from an outside surface of the retention bracket toward the interior of the body.

Abstract: A clothes deodorizing apparatus includes: a bag body for accommodating clothes; an ozone supply apparatus to supply air with the ozone into the bag body; a throwing inlet arranged on the bag body and opened and closed through a zipper; and a locking detection unit configured to detect that the throwing inlet is locked by the zipper. The locking detection unit includes: a detection lock connected with a slider of the zipper; and a lock detection part arranged on the ozone supply apparatus and configured to detect a lock inserting concave part that accepts the detection lock and the detection lock. The detection lock does not reach the lock inserting concave part in a state that the zipper is completely opened, and reaches the lock inserting concave part in a state that the zipper is completely closed.

Abstract: Aspects of the disclosure include an attachment for providing a scent to a container. In some aspects, a scent delivery system includes a bottle including a collar and a ledge structure each extending circumferentially outward; a scent ring loaded with a volatile chemical agent to emanate and generate a scent and including an interior protruding structure projecting from an interior wall of the ring, the scent ring configured to fasten around the neck of the bottle based on contact between the interior protruding structure and the ledge structure of the bottle; and a cap reversibly attachable to the bottle and including an interior rim structure that circumferentially projects from the interior of the cap, where the cap is structured to enclose the scent ring in a compartment formed between the collar and the interior rim structure when the cap is securely fastened to the bottle and trap the scent.

Abstract: The invention provides a solid foam wound dressing useful for hemorrhage control and wound repair, as well as methods for making such a wound dressing.

Abstract: A hemostatic device for promoting the clotting of blood includes a gauze substrate, a clay material disposed on the gauze substrate, and also a polyol such as glycerol or the like disposed on the gauze substrate to bind the clay material. When the device is used to treat a bleeding wound, at least a portion of the clay material comes into contact with blood emanating from the wound to cause the clotting. A bandage that can be applied to a bleeding wound to promote the clotting of blood includes a flexible substrate and a gauze substrate mounted thereon. The gauze substrate includes a clay material and a polyol. A hemostatic sponge also includes a gauze substrate and a dispersion of hemostatic material and a polyol on a first surface of the substrate.

Abstract: A releasably adhesive laminate (1) comprises a structural layer (2) carrying on at least part of one side thereof a hydrophobic gel (4) and on at least part of the other side thereof a pressure-sensitive adhesive (3). The structural layer (2) is preferably a film of synthetic plastics material, eg polyurethane. The pressure-sensitive adhesive (3) is preferably an acrylic adhesive, and the hydrophobic gel (4) is preferably a silicone gel. The laminate (1) may be used as a skin contact component of a wound dressing or in numerous other applications.

Abstract: This disclosure provides novel hydrogels that can undergo multiple gel-sol transitions and methods of making and using such hydrogels, particularly in anastomosis procedures. The peptide hydrogels comprising a fibrillar network of peptides that are in an amphiphilic ?-hairpin conformation. The peptides comprise photo-caged glutamate residues with a neutral photocage that can be photolytically selectively uncaged to disrupt the fibrillar network and trigger an irreversible gel-sol phase transition of the hydrogel. Isolated peptides for making the disclosed hydrogels are provided, as are methods of using the peptide hydrogels in anastomosis procedures.

Abstract: Absorbable medical devices based on novel foams and films made from semi-crystalline, segmented copolymers of lactide and epsilon-caprolactone exhibiting long term absorption characteristics are disclosed. Also disclosed are methods of producing said foams and films, and useful polymer solutions.

Abstract: One aspect of the present disclosure relates to a method for forming a multipurpose membrane in vivo. One step of the method includes obtaining a blood component. Next, a vacuum assembly is operated to remove substantially all of the liquid from the blood component and thereby form a concentrated, substantially dehydrated blood component. The substantially dehydrated blood component is then formed into a non-coagulated injectable composition and administered to a wound of a subject.

Abstract: This invention relates to a biomaterial comprising an injectable bioresorbable polysaccharide composition wherein the polysaccharide may be succinochitosan glutamate. This invention also relates to a biomaterial comprising an injectable bioresorbable polysaccharide composition in which resorbable particles may be in suspension, the said particles comprising or consisting essentially of chitin and/or chitosan, which may be free of any additional formulation modifying agents, and a process for manufacturing the same. This invention also relates to a medical device including said biomaterial and to a method of repair or treatment including the filling of cavities in the human face or body.

Abstract: The invention relates to the field of pharmaceutical compositions. More particularly it is directed to substance delivery system (or implant), such as scaffolds and membranes, comprising an anabolic drug, such as a Fibroblast Growth Factor 18 (FGF-18) compound, to methods of producing such delivery system, as well as use thereof. The implants according to the invention are for use for the treatment of cartilage disorders, such as osteoarthritis, cartilage injury or osteochondral defects.

Abstract: A porous matrix suitable for use as a tissue scaffold is described. The matrix may be shaped before insertion into or at the target tissue site, or injected via a minimally invasive method. The matrix may be pre-seeded with cells of the target tissue or may be used to support growth of the local endogenous tissue. The matrix may contain growth factors or other pharmacologically acceptable moieties such as antibiotics.

Abstract: Provided are antimicrobial solutions, including catheter lock solutions. In some embodiments, the solution contains an antibiotic (e.g., minocycline or trimethoprim), EDTA, and an alcohol (e.g., ethanol), wherein the pH of the solution is adjusted to about 6-8 to reduce precipitation. Methods of using the solutions and kits are also provided.

Abstract: An anchorage device comprising a mesh substrate coupled to an implantable medical device is disclosed, where the mesh substrate has a coating comprising a polymer, and the mesh further comprises at least one active pharmaceutical ingredient. The active pharmaceutical agent is designed to elute from the mesh over time. The mesh substrate can be configured to reduce the mass of the anchorage device such that tissue in-growth and/or scar tissue formation at the treatment site is reduced. In some embodiments, the mesh substrate can be formed with a mesh having a low areal density. In some embodiments, the mesh substrate can include one or more apertures or pores to reduce the mass of the substrate.

Abstract: Adjunct material retained by a staple cartridge assembly is provided. The adjunct material provides elution of medicants therefrom such that release of one medicant regulates release of another medicant. A first medicant is released as a bolus dose substantially immediately upon delivery of the adjunct material to tissue. The second medicant is associated with the staple cartridge assembly in a manner such that release of the second medicant to tissue is regulated by the release of the first medicant.

Abstract: Systems, methods, and dressings are presented that involve using a RFID device in a dressing to provide pressure data or other data to a remote base unit. The dressing is an interactive dressing. The reduced pressure in the dressing may be monitored and used to control delivery of reduced pressure. In one instance, the pressure data at each dressing allows a plurality of tissue sites to be monitored and used with as single remote base unit. In another instance, devices and methods for assuring a proper pairing of reduced-pressure dressings and remote base units are also presented. Other systems, methods, and dressings are presented.

Abstract: A method and apparatus for injecting saline into an open cavity of a patient's body, and, alternatively, vacuuming fluids from said cavity, during laparoscopic surgery that provides constant feed and amplified pressure to provide a steady fluid output, in a disposable, single use handheld surgical device. The apparatus has a pump portion that includes a vacuum powered pump motor with a spring-biased valve.

Abstract: Fluid supply systems and methods for therapeutic fluid delivery systems, including those used for negative pressure wound therapy (NPWT) systems and methods.

Abstract: An adapter for use in a system for collecting colostrum and/or milk from a breast may include: a body having a predominantly cylindrical shape; a first open end of the body for connecting to a funnel device; a second open end of the body for connecting to a source of suction; a side port between the first and second ends for connecting to a fluid collection device; a catchment area at or near the side port; and a blocking member between the side port and the second end, for preventing colostrum from passing beyond the side port and through the second end. The blocking member may include at least one aperture for allowing suction force to be transmitted from the second end to the first end.

Abstract: A catheter pump is provided that includes a rotatable impeller and an elongate cannula. The elongate cannula has a mesh that has a plurality of circumferential members disposed about the impeller. The elongate cannula has a plurality of axial connector extending between a proximal side of a distal circumferential member and a distal side of a proximal circumferential member. The circumferential members are radially self-expandable. The cannula is configured to minimize fracture within at least in the distal zone of the mesh as the elongated cannula moves into a sheathing device.

Abstract: In order to produce a pulsatile blood flow pattern that includes time periods of relatively high blood flow rates and time periods of relatively low blood flow rates, the operating speed of a blood pump can be selectively controlled to produce an operating speed pattern that includes time periods of relatively high rotation speeds and periods of relatively low rotation speeds. For example, the blood pump is rotated at a first speed for a first period of time. The speed of the blood pump is then decreased from the first speed to a second speed and is operated at the second speed for a second amount of time. The speed of the blood pump is then decreased to a third speed for a third amount of time. If desired, the operating speed pattern can be repeated to continue the pulsatile blood flow pattern.

Abstract: An extracorporeal system for liver dialysis comprises a filter device having hollow fibers with integrated ion-exchange particles and hydrophobic adsorbent particles in the filtrate space. The system can be used for the treatment of acute liver failure and acute-on-chronic liver failure.

Abstract: In some aspects, a dialysis machine support assembly includes a platform configured to support a dialysis machine and a drive assembly configured to move the platform vertically.

Abstract: This disclosure relates to detecting fluid in medical tubing. In certain aspects, a method is performed by a data processing apparatus. The method includes controlling repetitive activation of the ultrasonic transmitter. The method also includes receiving a signal from the ultrasonic receiver during an activation of the ultrasonic transmitter. The method also includes determining that fluid is absent or present in a portion of the medical fluid tube based on a comparison between the signal and a threshold value.

Abstract: The present invention is directed to a method for removing cytokines and/or pathogens from blood or blood serum (blood) by contacting the blood with a solid, essentially non microporous substrate which has been surface treated with heparin, heparan sulfate and/or other molecules or chemical groups (the adsorbent media or media) having a binding affinity for the cytokine or pathogen(s) to be removed (the adsorbates), and wherein the size of the interstitial channels within said media is balanced with the amount of media surface area and the surface concentration of binding sites on the media in order to provide adequate adsorptive capacity while also allowing relatively high flow rates of blood through the adsorbent media.

Abstract: A detecting device for a medium inside a tube portion comprises at least one light source being arranged at a first position relative to the tube portion adapted to be transilluminated with light and being configured to irradiate light onto the tube portion, a detector unit being arranged at a second position relative to the tube portion and being configured to receive light from the at least one light source passed through the tube portion and to analyze a medium inside the tube portion in a spatially resolving manner, and a homogenizing device being arranged at a position between the at least one light source and the tube portion and being configured, for detecting and quantifying differences in brightness due to local differences of the medium inside the tube portion, to create a homogenous and/or isotropic distribution of the light from the at least one light source before the light enters into the tube portion.